Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1872 | IV Dexamethasone Wiki | 1.00 |
| drug2437 | Motivational social support from nurse with additional support from significant other Wiki | 1.00 |
| drug2501 | Nasal Dexamethasone Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007511 | Ischemia NIH | 0.35 |
| D003324 | Coronary Artery Disease NIH | 0.33 |
| D006331 | Heart Diseases NIH | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.33 |
| HP:0001658 | Myocardial infarction HPO | 0.22 |
Navigate: Correlations HPO
There is one clinical trial.
After a 30-year decline, heart disease is projected to increase up to 18% by 2030. Participation rates in cardiac rehabilitation remain extremely low and hopeless individuals are less likely to participate. This innovative study has the potential to advance science, improve patient care, and improve patient outcomes by demonstrating the effectiveness of the Heart Up! program to increase physical activity and reduce hopelessness in patients with heart disease. Hopelessness is associated with a 3.4 times increased risk of mortality or nonfatal myocardial infarction in patients with ischemic heart disease (IHD), independent of depression. Hopelessness has been identified in 27-52% of patients with IHD and can persist for up to 12 months after hospital discharge. Hopelessness, a negative outlook and sense of helplessness toward the future, can be a temporary response to an event (state) or a habitual outlook (trait). Hopelessness is associated with decreased physical functioning and lower physical activity (PA) levels in individuals with IHD. While research has investigated strategies to increase PA among IHD patients in general, the study team is the only group to design an intervention to promote PA specifically in hopeless IHD patients. The purpose of this randomized controlled trial is to establish the effectiveness of our 6-week mHealth intervention (Heart Up!) to promote increased PA in hopeless patients with IHD. A total of 225 hopeless IHD patients will be enrolled from a large community teaching hospital in the Midwest. Patients will be randomized (75 per group) to one of three groups: 1) motivational social support (MSS) from a nurse, 2) MSS from a nurse with additional significant other support (SOS), or 3) attention control (AC). It is hypothesized that 1) The MSS with SOS group will have the greatest increase in average minutes of moderate to vigorous PA per day at 8 and 24 weeks as compared to the MSS only or AC groups; 2) Greater increase in minutes of moderate to vigorous PA per day will be associated with decreased state hopelessness levels from baseline to weeks 8 and 24; and 3) Increased social support and increased motivation will mediate the effects of Heart Up! on a greater increase in moderate to vigorous PA at 8 and 24 weeks. The findings from this study could transform care for IHD patients who are hopeless by promoting self-management of important PA goals that can contribute to better health outcomes.
Description: Mean minutes/day moderate to vigorous physical activity
Measure: ActiGraph GT9X Link Accelerometer Time: Month 12Description: Participant's report of current level of state hopelessness. Total score range= 1 (better) to 4 (worse).
Measure: State-Trait Hopelessness Scale Time: Month 12Description: Participant's report of exercise self-regulation level. Total score range= 1 (worse) to 7 (better).
Measure: Exercise Self-Regulation Questionnaire Time: Month 12Description: Participant's report of perceived social support level. Total score range= 1 (worse) to 30 (better).
Measure: ENRICHD Social Support Inventory Time: Month 12Description: Comorbidity score based on medical record abstraction. Total score range= 0 (better) to 100 (worse).
Measure: Charlson Comorbidity Index Time: Week 1Description: Participant's report of participation level with exercise in home, community or cardiac rehabilitation program
Measure: Cardiac Rehabilitation Exercise Participation Tool Time: Month 12Description: Participant's report of mean level of depressive symptoms. Total score range= 0 (better) to 27 (worse).
Measure: Patient Health Questionnaire-9 Time: Month 12Description: Participant's report of mean level of well-being. Total score range= 4 (better) to 20 (worse).
Measure: PROMIS-29 Time: Month 12Description: Participant's report of mean level state and trait hope. Total score range= 8 (worse) to 64 (better).
Measure: Snyder State Trait Scales Time: Month 12Description: Participant's report of mean level of quality of life. Total score range= 1 (better) to 5 (worse).
Measure: EuroQol (EQ-5d-5L) Time: Month 12Description: Participant's report of COVID-19 symptoms, diagnosis, testing, and social distancing. No score range (14 items).
Measure: Multi-Ethnic Study of Atherosclerosis (MESA) COVID-19 Questionnaire Time: Month 12Description: Participant's report of impact on routine; income/ employment; access to food, medical and mental health care, extended family; and stress. No range (12 items)
Measure: Coronavirus Impact Scale Time: Month 12Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports